Entacapone 200mg tablet by mouth, three times a day and then increasing to 400mg tablet by mouth, three times a day until disease progression, intolerable toxicity, or withdrawal of informed consent, whichever occurs first.
And Imatinib mesylate 400mg tablet by mouth, once a day until disease progression, intolerable toxicity, or withdrawal of informed consent, whichever occurs first.

Gastrointestinal Stromal Tumor, Malignant

Entacapone

Imatinib Mesylate

Bin Li, MD

Entacapone Combination With Imatinib for Treatment of GIST

Entacapone in Combination With Imatinib Mesylate for Treatment of Patients With Gastrointestinal Stromal Tumors(GIST) Following Failure of at Least Imatinib and Sunitinib

the total proportion of patients with reduction in tumor burden of a predefined amount. The ORR is the sum of complete response(CR)+partial responses(PR) per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1

the total proportion of patients who demonstrate a response to treatment. The DCR is the sum of complete response(CR)+partial responses(PR)+ stable disease(SD) per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1

De-identified individual participant data for all primary and secondary outcome measures will be made available.

Lun-Quan Sun

Director of Center for molecular medicine, Xiangya hospital, Central South University

Xiangya Hospital of Central South University

Group K +: cancer of the upper aerodigestive tract with or without cachexia

Group K-: absence of cancer and absence of cachexia

The MYOMEC study includes the inclusion of healthy patients (to form a control group

Cancer of Upper Aerodigestive Pathways

Cachexia

carcinological surgery

cervical surgery

CHU Clermont-Ferrand

Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract

The ratio of ATP produced by mitochondria and oxygen consumed by muscle mitochondria

(Expression of cytochrome c oxidase, citrate synthase, HAD, complexes 1, 2 and 3 of the mitochondrial respiratory chain)

(Muscular ceramide concentration, DAG and TAG)

myosteatosis (Computed tomography in L3 for quantification in Hounsfield units)

(phosphorylation rate of mTOR and EiF2alpha)

(Expression of MURF1 and MAF-box ligases)

(Insulinemia, Fasting Glycemia, Hepatic and Lipid Assessment, CRP, Albumin, Pre-albumin, Blood Ionogram, Inflammatory Markers)

University Hospital, Clermont-Ferrand

Previously collected tissue samples are analyzed for K-ras mutations; COX-2, phospho-AKT, and VEGF overexpression; microvessel density; association of genomic instability with microsatellite instability and p53 mutations; and methylation status of MLH1, MGMT, and WRN and to identify prognostic biomarkers by LINE-1 hypomethylation, PIK3CA mutation, BRAF mutation, FASN expression, and VDR expression via immunohistochemistry, PCR, RT-PCR, and microarray.

Colorectal Cancer

laboratory biomarker analysis

Brigham and Women's Hospital

Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581

Correlative Science Studies in Colon Cancer a Companion Study to CALGB 9581 and 89803

Using stratified analyses, effect modification by molecular alterations will be assessed. To maintain statistical power, body mass index and physical activity will be categorized into tertiles for the analyses of interactions with tumor molecular alterations. To assess whether the relative effect of an exposure differs according to the presence of the molecular alteration, tests for statistical interaction will be performed by entering into the model the cross-product term of the molecular alteration (as an indicator variable) and the other risk factor for cancer recurrence.

Proper adjustment for multiplicity must be applied.

Will use the Kaplan Meier product-limit estimator.

Weighted Cox proportional hazards regression models will be fit and Wald-type test statistics for the model parameters will be constructed using weighted partial likelihood estimates and robust variance estimates.

Interaction hazard ratios and the Cox model will be used.

It is also planned to establish whether this correlates with response to the camptothecin-related compound irinotecan hydrochloride.

sarcoma/obezita

Entacapone Combination With Imatinib for Treatment of GIST

Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract

Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581

Late Effects of Treatment for Sarcomas in Children

Najkompletnejšia databáza liečivých bylín podporovaná vedou